Description of Program Applications are being solicited for support by the American Cancer Society‐Institutional Research Grant (IRG). These funds are designed to provide seed money to support junior faculty members with an interest in cancer research who do not have external grant support. The ACS defines junior faculty as investigators at the rank of assistant […]

Many women who receive chemotherapy for breast cancer report problems with their thinking, memory and attention after treatment. And as the survival rates for breast cancer increase, so do these issues associated with chemotherapy. Paul Newhouse, M.

For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. The new CAR-T investigational therapy (known as KTE-C19) is being studied in a clinical trial for patients with aggressive non-Hodgkin Lymphoma (NHL). The trial, called […]

Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis. That head injury may have […]

Leora Horn, M.D., M.

Histone deacetylases (HDACs) are enzymes that modulate gene expression and have important roles in development and disease. HDAC inhibitors are active against lymphoma, and understanding the roles of specific HDACs is important for further therapeutic development. Scott Hiebert, Ph.

The annual Chic Awearness fundraising event that supports ovarian cancer research at major medical centers, including Vanderbilt University Medical Center (VUMC), will be held Monday, Sept. 25, 6:30 – 8:

Vanderbilt University Medical Center is the world’s first site to treat a patient in the TULSA-PRO Ablation Clinical Trial (TACT), which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation. Investigators, David Penson, M.D.

Justin Balko, Pharm.D., Ph.

Leading cancer investigators from Vanderbilt-Ingram Cancer Center will unveil the latest in cancer research during an upcoming community event. “Precision Medicine in Cancer: At the Crossroads of Research and Treatment for Patients” will be held Tuesday, May 10, from 5: